

Pfizer-BioNTech and Moderna COVID-19 vaccines – Emergency use authorization updated for additional dose for certain immunocompromised individuals

- On August 12, 2021, the <u>FDA approved</u> an amendment to the emergency use authorizations (EUAs) for both the <u>Pfizer-BioNTech COVID-19 vaccine</u> and the <u>Moderna COVID-19 vaccine</u> to allow for the use of an additional dose in certain immunocompromised individuals.
- The authorizations for these vaccines have been amended to allow for an additional, or third, dose
  to be administered at least 28 days following the two-dose regimen of the same vaccine to
  individuals 18 years of age or older (ages 12 or older for Pfizer-BioNTech) who have undergone
  solid organ transplantation, or who are diagnosed with conditions that are considered to have an
  equivalent level of immunocompromise.
- On August 13, the <u>CDC's Advisory Committee on Immunization Practices (ACIP)</u> held a meeting to discuss the updated vaccine EUAs in immunocompromised patients.
  - The Committee voted unanimously in favor of recommending an additional (third) dose of the Pfizer-BioNTech (≥ 12 years) or Moderna (≥ 18 years) vaccine following a primary series in immunocompromised people.
- The updated EUA for the Pfizer-BioNTech vaccine was supported by a single arm study in 101 individuals who had undergone various solid organ transplant procedures (heart, kidney, liver, lung, pancreas). A third dose of the Pfizer-BioNTech COVID-19 was administered to 99 of these individuals approximately 2 months after they had received a second dose.
  - Among the 59 patients who had been seronegative before the third dose, 44% were seropositive at 4 weeks after the third dose. All 40 patients who had been seropositive before the third dose were still seropositive 4 weeks later. The prevalence of anti-SARS-CoV-2 antibodies was 68% four weeks after the third dose.
- The updated EUA for the Moderna COVID-19 vaccine was supported by a randomized-controlled study in 120 individuals who had undergone various solid organ transplant procedures (heart, kidney, kidney-pancreas, liver, lung, pancreas). A third dose of the Moderna COVID-19 vaccine was administered to 60 individuals approximately 2 months after they had received a second dose; saline placebo was given to 60 individuals for comparison.
  - Significant increases in levels of SARS-CoV-2 antibodies occurred four weeks after the third dose in 55.0% of the Moderna COVID-19 vaccine group and 17.5% of the placebo group.
- Currently, the FDA is not authorizing an additional dose of COVID-19 vaccine in the general population who are fully vaccinated and there is no recommendation yet for using booster doses in non-immunocompromised individuals



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

 $\mbox{RxNews}^{\tiny{\textcircled{\tiny{\scriptsize 0}}}}$  is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.